Stocks Added to Zacks Rank 5 (Strong Sell) List - 89bio Inc (ETNB) is a clinical-stage biopharmaceutical company with a 38 8% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Altice USA Inc (ATUS) is a broadband communications and video services provider with a 250% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [1] - Ashland Inc (ASH) is an additives and specialty ingredients provider with a 16 2% downward revision in the Zacks Consensus Estimate for current year earnings over the last 60 days [2]

Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin.  The Avoca business line ...

As an investment analyst with 3 years of experience in the finance sector, I specialize in analyzing market trends, conducting thorough financial assessments, and providing actionable investment recommendations. My expertise lies in momentum and factor investing, where I utilize a blend of quantitative and qualitative methods to identify opportunities and manage risks.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate a ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Ashland Inc. (ASH) : is a additive and specialty ingredients provider. The Zacks Consensus Estimate for its current year earnings has been revised 15% downward over the last 60 days.Baidu, Inc. (BIDU) is an online marketing and cloud services provider. The Zacks Consensus Estimate for its current year earnings has been revised 9% downward over the last 60 days.Evolent Health, Inc. (EVH) is a health service company. The Zacks Consensus ...

HIBISCUS phase 2 data evaluating the safety profile and efficacy of etavopivat in adult and adolescent patients with sickle cell diseaseFRONTIER4 interim phase 3 results evaluating safety profile and efficacy of Mim8 prophylaxis administered once every two weeks for patients with haemophilia A with or without inhibitorsExplorer7 phase 3 study results evaluating the safety profile and efficacy of concizumab in patients with haemophilia A or B with inhibitors, with or without target joints at baseline Bagsvær ...

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the American So ...

SAN DIEGO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will be hosting a virtual investor event at 8:00 a.m. ET / 5:00 a.m. PT on Monday, December 9, 2024, to discuss the KOMET-007 combination trial of the Company’s oral and selective menin inhibitor, ziftomenib, following the presentation of updated clinical data at the 66th Amer ...

SAN FRANCISCO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the company will host a live webcast to review new clinical data from the ongoing Phase 1a/1b clinical trial of its Bruton’s tyrosine kinase (BTK) degrader program NX-5948, and provide a corporate update, at 8:15 p.m. PT (11:15 p.m. ET) on Monday, ...

75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented on Monday, December 9, 2024 at 4:00 PM PT LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and select immune-mediated diseases, today announced that additional NEXICART-1 NXC-201 clinical data in relaps ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission file number 333-211719 ASHLAND INC. Delaware (State or other jurisdiction of incorporation or organization) 81-2587835 (I.R.S. Employer I ...